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Background: A variety of oncogenic and environmental factors alter tumor metabolism to serve the distinct
cellular biosynthetic and bioenergetic needs present during oncogenesis. Extracellular acidosis is a common
microenvironmental stress in solid tumors, but little is known about its metabolic influence, particularly when
present in the absence of hypoxia. In order to characterize the extent of tumor cell metabolic adaptations to
acidosis, we employed stable isotope tracers to examine how acidosis impacts glucose, glutamine, and palmitate
metabolism in breast cancer cells exposed to extracellular acidosis.
Results: Acidosis increased both glutaminolysis and fatty acid β-oxidation, which contribute metabolic intermediates
to drive the tricarboxylic acid cycle (TCA cycle) and ATP generation. Acidosis also led to a decoupling of glutaminolysis
and novel glutathione (GSH) synthesis by repressing GCLC/GCLM expression. We further found that acidosis redirects
glucose away from lactate production and towards the oxidative branch of the pentose phosphate pathway (PPP).
These changes all serve to increase nicotinamide adenine dinucleotide phosphate (NADPH) production and
counter the increase in reactive oxygen species (ROS) present under acidosis. The reduced novel GSH synthesis
under acidosis may explain the increased demand for NADPH to recycle existing pools of GSH. Interestingly,
acidosis also disconnected novel ribose synthesis from the oxidative PPP, seemingly to reroute PPP metabolites
to the TCA cycle. Finally, we found that acidosis activates p53, which contributes to both the enhanced PPP and
increased glutaminolysis, at least in part, through the induction of G6PD and GLS2 genes.
Conclusions: Acidosis alters the cellular metabolism of several major metabolites, which induces a significant degree
of metabolic inflexibility. Cells exposed to acidosis largely rely upon mitochondrial metabolism for energy generation
to the extent that metabolic intermediates are redirected away from several other critical metabolic processes,
including ribose and glutathione synthesis. These alterations lead to both a decrease in cellular proliferation and
increased sensitivity to ROS. Collectively, these data reveal a role for p53 in cellular metabolic reprogramming under
acidosis, in order to permit increased bioenergetic capacity and ROS neutralization. Understanding the metabolic
adaptations that cancer cells make under acidosis may present opportunities to generate anti-tumor therapeutic agents
that are more tumor-specific.* Correspondence: jentsan.chi@duke.edu
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Tumor metabolism is essential to meet the various meta-
bolic demands associated with the proliferation and expan-
sion of tumor cells. These needs fall into several categories,
including: (i) bioenergetics (ATP and other energy equi-
valents required for energy homeostasis); (ii) biosynthetic
(biochemical intermediates required for the synthesis of
macromolecules for cell proliferation such as fatty acids
and nucleotides); and (iii) reductive capacity (for example,
nicotinamide adenine dinucleotide phosphate (NADPH))
for a variety of biochemical reactions to neutralize in-
creased reactive oxidative stress (ROS). Perhaps the most
prominent example of altered tumor metabolism is the in-
creased glucose utilization and excessive production of
lactic acid in many solid tumors, termed the ‘Warburg’ ef-
fect [1]. The continuous expansion of tumor cells be-
yond the capacity of local vascular perfusion leads to a
variety of environmental alterations, such as oxygen
depletion (hypoxia), glucose deprivation, high lactate
levels (lactosis), and extracellular acidosis [2-8]. These
microenvironmental stresses exert important influences
on gene expression and metabolic phenotypes. For ex-
ample, hypoxia induces expression of genes involved in
the transport and metabolism of glucose [9,10] while
restricting the entry of metabolites into the mitochon-
dria by activating pyruvate dehydrogenase kinase (PDK)
[11,12]. Hypoxia also renders cells reliant on the reductive
carboxylation of glutamine-derived α-ketoglutarate (α-KG)
for de novo lipogenesis [13,14]. Compared with hypoxia,
relatively little is known about the metabolic adaptations in
response to acidosis. Previous studies have suggested
that acidosis can influence hypoxia responses, inhibit gly-
colysis and trigger autophagy [5,6,15,16]. In renal cells,
metabolic acidosis increases glutamine and glutamate me-
tabolism [17,18]. However, many details about the cellular
metabolic reprogramming under acidosis remain unknown.
NADPH plays a crucial role in the defense against ROS
and reductive biosynthetic reactions (for example, lipoge-
nesis) to fuel macromolecular biosynthesis. One key source
of NADPH is the pentose phosphate pathway (PPP), by
which glycolysis intermediates (for example, glucose-6-
phosphate (G6P)) are used to generate NADPH and
ribose-5-phophsate (R5P). The PPP possesses an oxida-
tive and non-oxidative branch, both of which have been
demonstrated to be activated or overexpressed in human
cancer. In the oxidative branch, glucose-6-phosphate
dehydrogenase (G6PD or G6PDH) is the first and rate-
limiting enzyme, non-reversibly oxidizing G6P to 6-P-
gluconolactone, a reaction which generates NADPH.
G6PD deficiency in humans impairs the generation of
NADPH, leading to significant red cell lysis and anemia
due to oxidative stress. The non-oxidative branch of the
PPP is mediated by the reversible reactions of several
transketolases (TKT, TKTL1, TKTL2) and transaldolase,which generate the sugar moiety of the nucleotide precur-
sor R5P for nucleotide synthesis during proliferation.
Since the non-oxidative PPP is reversible, any excess
amount of pentose phosphate can be converted back to
glycolysis when bioenergetic (ATP) requirements exceed
biosynthetic need (for example, R5P). Beside glucose, both
glutamine and several fatty acids (via acetyl-CoA) can
function as substrates for various bioenergetic and biosyn-
thetic processes. Glutamine in particular serves as a sub-
strate for a variety of cellular processes, including citrate
synthesis and lipogenesis [13,14], de novo synthesis of
glutathione, and as carbon source for the canonical tri-
carboxylic acid cycle (TCA cycle) via α-KG.
Recently, various mass-spectrometry-based metabolo-
mics techniques have been used to measure the steady-
state levels of metabolites and quantitate metabolic flux
[19,20]. These approaches have identified metabolites as-
sociated with tumor progression [19-21] and the process
of reductive carboxylation of glutamine to citrate [14].
No similar approach has yet been applied to define the
effect of acidosis. Here, we applied stable-isotope tracer
measurements to define how acidosis affects cellular
metabolism. Together with measurements of intracellu-
lar amino acids and transcriptional profiling of cancer
cells under acidosis [6], these data reveal extensive
metabolic reprogramming and critical metabolic adap-
tations that offer the opportunity to target cancer cells
selectively under acidosis.
Methods
Cell culture and modeling various microenvironmental
stresses
MCF-7, ZR-75-1, T47D, MDA-MB-231 and MDA-MB-157
cells were cultured in RPMI with 2.0 g/l glucose, 10% fetal
bovine serum, 1 × antibiotics (penicillin, 10,000 UI/ml;
streptomycin, 10,000 UI/ml) and 25 mM 2-[4-(2-hydro-
xyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES). Cell
lines, obtained from and initially validated by the Duke
Cell Culture Facility (Durham, NC, USA), were main-
tained for fewer than 6 months and validated by mi-
croscopy every 1 to 2 days. Lactosis was generated via
addition of sodium lactate (Sigma), while acidosis was
generated via media pH adjustment to pH 6.7 by HCl.
For the α-KG rescue experiments, media was supple-
mented with 700 μM dimethyl α-KG (Sigma-Aldrich (St.
Louis, MO, USA). The paired shp53 and shControl MCF-7
cells were as previously described [22]. Control or gene-
specific small interfering (si)RNAs (Additional file 1: Table
S1; Ambion/Life Technologies (Grand Island, NY, USA))
were transfected using lipofectamine 2000 in OPTIMEM
according to the manufacturer’s instructions. The cDNA
expression constructs for nuclear factor erythroid 2-related
factor 2 (NRF2) were purchased from Origene (Rockville,
Md, USA) and described previously [23], while cDNA
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Dr Zhaohui Feng from the Robert Wood Johnson Med-
ical School (New Brunswick, NJ, USA) [24]. The effi-
ciency of silencing was determined by western blots.
Stable isotope labeling experiments
A total of 2 × 106 MCF-7 cells were plated in 10 cm dishes
in quadruplicate. After 24 h, the media was changed to
media containing either 2 g/l glucose (50% (1 g/l) (1,2-13C2)
D-glucose and 50% (1 g/l) unlabeled glucose), 2 mM (100%
(uniformly-labeled U-13C)) glutamine or 10 μM (U-13C)
palmitate. Cells were exposed to control or acidosis
(pH 6.7) media for 24 h. Culture medium (for CO2, glu-
cose, glutamate, and lactate isotopomer measurements)
and cell pellets (for palmitate and ribose measurements)
were collected after cells were washed twice in 1 × PBS,
harvested via cell scraping on ice, and specific extractions
were performed as described below and as previously re-
ported [25].
The procedures for extraction and derivatization of
glucose, cholesterol, ribose, fatty acids, lactate, CO2 and
glutamate have been previously published [26,27]. Fatty
acids were extracted by saponification of Trizol (500 μl,
Invitrogen, Carlsbad, CA, USA) cell extract, after removal
of the upper glycogen-containing and RNA-containing
supernatant, using 30% KOH and 70% ethanol (300 μl
each) for 2 h. Fatty acids were extracted by further acidifi-
cation using 6 N hydrochloric acid to a pH below 2.0 and
repeated vortexing with 5 ml petroleum ether. Fatty acids
(palmitate) were monitored at m/z 270, using canola oil as
positive control. The enrichment of acetyl units in media
and cell pellet palmitate in response to acidosis was deter-
mined using the mass isotopomer distribution analysis
(MIDA) approach. Acetyl-CoA and fractions of new syn-
thesis were calculated from the M4/M2 ratio using the
formula M4/M2 = (n - 1)/2•(p/q), where n is the number
of acetyl units, p is the 13C labeled precursor acetate
fraction and q is the 12C-labeled natural acetate fraction
(p + q = 1) [28].
For glucose extraction, 500 μl each of 0.3 N barium hy-
droxide and 0.3 N zinc sulfate were added to 100 μl media.
Samples were vortexed and centrifuged for 15 minutes at
10,000 rpm. The supernatant was then dried on air over
heat and were derivatized by adding 150 μl hydroxylamine
solution and incubated for 2 h at 100°C followed by
addition of 100 μl of acetic anhydride. Samples were incu-
bated at 100°C for 1 h and dried under nitrogen over heat
as previously described in the fatty acids derivatization
section. Ethyl acetate (200 μl) was added. Peak glucose ion
was detected at the m/z 187 cluster.
Lactate was extracted from media through acidification
of 100 μl media with HCl and addition of 1 ml of ethyl
acetate. The resulting aqueous layer was dried under ni-
trogen over heat and derivatized using lactate standardsolution as positive control. A total of 200 μl of 2,2-
dimethoxypropane was added followed by 50 μl of 0.5 N
methanolic HCl. Samples were incubated at 75°C for 1 h.
Then, 60 μl of n-propylamine was added and samples were
heated for 100°C for 1 h followed by addition of 200 μl di-
chloromethane. Heptafluorobutyric anhydride (15 μl) was
added followed by 150 μl of dichloromethane and samples
were subjected to gas chromatography/mass spectrometry
(GC/MS). M1 and M2 lactate were differentiated to distin-
guish the pentose phosphate flux from anaerobic glycolysis
[25,28] and the ion cluster at m/z 328 was examined.
Media glutamate was converted into its n-trifluoroacteyl-
n-butyl derivative and monitored at ion clusters at m/z152
and m/z198. 13CO2 Assay for CO2 was generated by adding
equal volumes (50 μl) of 0.1 N NaHCO3 and 1 N HCl to
spent media and 12CO2/
13CO2 ion currents were moni-
tored and calculated from the m/z44 and m/z45 peak in-
tensities, respectively, using 13CO2/
12CO2 of in house cell
culture cabinet’s CO2 tank as the reference ratio for
13CO2
Δ calculations. This ratio of 13CO2/
12CO2 was determined
with gas chromatography-mass spectrometry (Agilent, Palo
Alto, CA, USA, 5975 MS and 6890 N (network) GC system
for volatile (gas) isotopomer data acquisitions,) as pre-
viously described [29].
Isolation of RNA ribose was performed as previously
reported [30]. Briefly, RNA ribose was first isolated by
acid hydrolysis of cellular RNA after Trizol purification
from cell pellets. Total RNA abundance was then quan-
tified by spectrophotometric determination in quadrupli-
cate. Cellular ribose was derivatized to its aldonitrile
acetate form using hydroxylamine, resuspended in pyri-
dine with acetic anhydride (Supelco/Sigma-Aldrich, St.
Louis, MO, USA) before mass spectral analyses. The ion
cluster was measured around m/z 256 (carbons 1 to 5 of
ribose; chemical ionization (total ribose)), m/z 217 (car-
bons 3 to 5 of ribose (non-oxidative branch ribose)), and
m/z 242 (carbons 1 to 4 of ribose; electron impact
ionization (oxidative branch ribose)) to determine molar
enrichment and the positional distribution of 13C in
ribose.
An Agilent (Palo Alto, CA, USA) 5975 Inert XL Mass
Selective Detector connected to HP6890N network gas
chromatograph was used to detect mass spectral data
under the following settings: GC inlet 230°C, MS source
230°C, MS quad 150°C [27]. For media CO2, glucose,
lactate and glutamate analyses, an HP-5 column (30 m
length × 250 μm diameter × 0.25 μm thickness) was used
while a DB-23 column (60 m length, 250 μm diameter ×
0.15 μm thickness) was used for fatty acid measurement.
Statistics for mass spectral analyses were obtained by
consecutive and independent injections of 1 μl sample
using an autosampler with optimal split ratios for column
loading (106 > abundance > 104 abundance). Data was ac-
cepted if the standard sample deviation was below 10% of
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currents; 100%) among repeated injections. Data down-
load was performed in triplicate manual peak integrations
using modified (background subtracted) spectra under the
overlapping isotopomer peaks of the total ion chro-
matogram (TIC) window displayed by the Chemstation
(Agilent, Palo Alto, CA, USA) software. A two-tailed in-
dependent sample t test was used to test for significance
(*P <0.05, **P <0.01) between control and treated groups.
Rapid system-wide association study (SWAS) evalu-
ation of MCF-7 cells was performed by the color assisted
visual isotopolome data matrix screening tool [26], to
diagnose phenotypic differences and response to acidosis.
The isotope labeled fractions, after subtracting natural 13C
enrichment, of all metabolic products from the 13C tracer
were found in total ion currents, obtained by chromatog-
raphy separation in the selected ion monitoring (SIM)
mode. These SIMs included all isotope labeled products
with the range that covers all possible single and multiple
substitutions, based on the number of carbons making up
the reported biomolecules and their fragment. The sum of
all labeled isoforms were then generated by the number
of 13C substitutions, expressed as labeled fraction, of
which positional 13C isoforms were normalized to 100%
and expressed as fractions (Σμ) of the 13C labeled portion
of the molecule. The sum of all labeled isoforms was also
weighed by the number of 13C position, expressed as 13C
content (Σμν). This number is also known as total activity
(isotope accumulation) when radiating isotopes are used.
Amino-acid profiling
The measurement of intracellular amino acids was per-
formed using stable isotope dilution techniques, flow injec-
tion tandem mass spectrometry and sample preparation
methods described previously [31,32]. Quantification was
facilitated by the use of stable isotope internal standards as
published [32].
RNA isolation and real-time PCR analysis
RNA was extracted using the miRVANA kit (Ambion).
A total of 1 μg of total RNA was reverse transcribed by
SuperScript II (Invitrogen) for real-time PCR with Power
SYBRGreen Mix (Applied Biosystems/Life Technologies
(Grand Island, NY, USA)) and primers for indicated
genes (Additional file 1: Table S1).
Cell viability assays
Cell viability was primarily evaluated by direct cell
counting (trypan blue exclusion), propidium iodide (PI)
and 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium
bromide (MTT) assays (Promega (Madison, WI, USA)).
For direct cell counting, 48 h after siRNA transfection,
stresses were applied (T = 0) and cells were counted at
the indicated timepoints, with two separate countsaveraged after trypan blue exclusion. For PI, cells were
washed twice with 1 × PBS, frozen at -80°C, thawed
then treated with 1:10 PI (5 μg/μl) for 30 minutes then
absorbance measured at 570 nm. For MTT assays,
MTT (5 μg/ml) was added to cell media at 1:10 for 3 h.
Afterwards, media was removed and cells resuspended
in dimethylsulfoxide (DMSO), then absorbance was
measured at 570 nm. The impact of lactic acidosis and
acidosis on viability are normalized against correspond-
ing control samples for each time point.NADP+/NADPH, glutathione (GSH)/glutathione disulfide
(GSSG), and total GSH measurements
NADP+/NADPH measurements were performed using
the NADP+/NADPH and/or GSSG/GSH ratiometric kit
(AAT Bioquest (Sunnyvale, CA, USA)) according to sug-
gested protocols. Total GSH was measured using the
GSH-Glo kit (Promega (Madison, WI, USA)) according
to suggested protocols. Cells were plated and siRNA
knockdowns were performed as stated. After 24 h of ex-
posure to neutral (pH 7.4) or acidic (pH 6.7) conditions,
cells were lysed and stored at -80°C. Cell extracts were
treated with respective NADP+/NADPH, GSH/GSSG, or
GSH extraction buffers. The fluorescence was measured
at 530/590 nm (for NADPH) or 490/530 (for GSSG),
while total GSH was measured by luminescence, and
standardized using known GSH concentrations.Glutamine uptake
MCF7 cells were plated in 6-well/12-well plates at the dens-
ity of 800,000/200,000 cells per well. Once cells reached
more than 75% confluence, they were washed with 1× PBS
twice and then treated under the respective conditions for
the indicated time. Cells were then washed with 37°C
Krebs-Ringer-HEPES (KRH) buffer twice, followed by the
addition of 500 μl/200 μl KRH buffer containing 0.5 μCi/
0.2 μCi 14C-glutamine (Perkin Elmer (Waltham, MA, USA))
for 1 h at 37°C, and washed three times with 1 ml/400 μl
of ice-cold KRH buffer containing 20 mM glutamine to
quench the glutamine uptake. Finally, cells were lysed with
1 ml/400 μl radioimmunoprecipitationassay (RIPA) buffer
and the lysates were subjected to liquid scintillation count-
ing, and normalized by protein concentrations, measured
with Bradford assay.G6PD enzyme activity
G6PD enzyme activity based on resazurin was adapted
from [33]. Cells were plated for 24 h then lysed using
triton-X in tandem with G6PD reaction buffer. G6PD
activity was measured via fluorescence at 470/530 nm,
blanked against PBS only and normalized against control
conditions.
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Cellular ROS were measured by normalized lumines-
cence using the Oxiselect ROS detection assay (Cell Bio-
labs (San Diego, CA, USA)). Cells were plated overnight,
incubated for 30 minutes at 37°C with the 2’,7’-dichloro-
dihydrofluorescin (DCFH) dye and then lysed to meas-
ure luminescence at 490/530 nm against a DCF standard
curve.
Western blot analysis
MCF7 cells were washed twice with cold 1 × PBS after
24 h of stress and lysed by RIPA buffer. Then, 15 μg of
lysates were separated in 10% gels and probed by the
indicated antibodies for p53, G6PD, TKT (Cell Signaling
(Danvers, MA, USA)), GS (Abnova (Taipei, Taiwan)) and
GLS2 and β-tubulin (Cell Signaling (Danvers, MA, USA)).
Densitometry was generated using ImageJ (http://rsbweb.
nih.gov/ij/).
Measurements of glutamine, glutamate and ATP
The intracellular glutamine and glutamate levels in cell
lysates were measured using the glutamine/glutamate
detection kit (Sigma) and normalized by protein con-
tents. For the measurements of media glutamine, media
was immediately removed before washing cells and
stored overnight at -80°C, then measured as above. The
culture media used typically lack glutamate. For ATP
measurements, cells were lysed with 100 μl assay re-
agent, incubated for 5 minutes in the dark and ATP
measured using the one-step ATP-lite kit (Perkin-Elmer
(Waltham, MA, USA)), then normalized to protein
content.
Statistical analyses
The effects of each stress on gene expression and metab-
olites (on a log2 scale) were normalized to the control
through zero transformation by subtracting the expres-
sion levels of the control samples from stressed samples.
Error bars for the stable-isotope tracer figures are stand-
ard deviations from the mean. For all other graphs, sam-
ples sizes are indicated in the figure legends; P values
were derived by two-tailed t test except for cell growth
assays, which were calculated by two-way ANOVA.
These were followed, in the event of a significantly differ-
ent interaction term (between siControl + acidosis versus
siRNA+ acidosis), by a pairwise comparison using a two-
tailed t test. P values are indicated (*P ≤0.05, **P ≤0.001,
and ***P ≤0.0001) and error bars are standard errors of
the mean.
Results
The influence of acidosis on glucose metabolism
While previous studies have indicated that both acidosis
and lactic acidosis lead to discrete cellular metabolicalterations that are distinct from hypoxia [6], significant
details about these processes remain unknown. To thor-
oughly define the metabolic response to extracellular
acidosis, we performed stable-isotope tracing experi-
ments on MCF-7 breast cancer cells exposed to control
(pH 7.4) or acidic (pH 6.7) conditions for 24 h. We fo-
cused on acidosis, rather than lactic acidosis, to avoid
any potential complications resulting from the cellular
use of lactate as a metabolic substrate. In addition, we
chose a pH of 6.7 since that is within the range (ap-
proximately 6.5 to 7.0) of acidity that has been observed
in human tumors [34,35]. We cultured MCF-7 cells in
quadruplicate with each of three isotope tracers: glucose
(1,213C-glucose), glutamine (uniformly labeled (U)13C
glutamine) and palmitate (U13C palmitate). After 24 h,
we harvested both cells and culture media to compare
the fate of various isotopomers from each isotope tracer
under control and acidosis.
From the isotope-labeled 1,213C2-glucose, we com-
pared several metabolites (Figure 1A) including CO2,
lactate, glutamate, ribonucleic acids and fatty acids
(palmitate and oleate) under control and acidosis con-
ditions (the relative changes are shown in Figure 1, with
the complete data, provided as ONCOisobolome
matrix tables, in Additional file 1: Tables S2 and S3).
We observed an equal level of labeled medium glucose
after 24 h (Figure 1B), suggesting equal availability dur-
ing the experimental periods. Compared with control,
acidosis increased the abundance of total labeled 13C-
CO2 being produced from glucose (Figure 1C). We also
noted a relative decrease in the total labeled lactate and
13C2-labeled lactate, but an increase in 13C1-labeled lac-
tate (Figure 1D). Since C1 is oxidized to CO2 in the PPP,
the increase in C1-lactate, compared to C2-labeled lac-
tate suggests that glucose is increasingly redirected to
the PPP under acidosis. This is consistent with an in-
crease in the labeled CO2, where the PPP is the most
likely source (Figure 1C). The observed decrease in total
labeled lactate is consistent with previous reports of de-
creased glycolysis under acidosis [5,6]. Acidosis also
increased 13C2-labeled and 13C4-labeled glutamate
(Figure 1E), which results from one (13C2-labeled) or
two (13C4-labeled) rounds of the TCA cycle. Increased
glutamate labeling from glucose under acidosis indicates
increased glucose conversion to pyruvate, which can
enter the TCA cycle, consistent with an increased reli-
ance upon mitochondrial metabolism under acidosis
[5,6]. Interestingly, we also observed a >90% reduction
in ribose synthesis from glucose (Figure 1F), suggesting
that acidosis abolished most of the biosynthetic conver-
sion of glucose to ribonucleotides. Finally, we observed
an insignificant decrease in labeled fatty acids under
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Figure 1 The use of 13C glucose isotope tracers to analyze the glucose metabolism under acidosis. (A) Schematic graph indicating various
measured metabolites (and corresponding panels) in major metabolic pathways resulting from the 1,213C labeled glucose tracer (green). 13C
labeled and unlabeled carbons are indicated in red and black, respectively. (B-G) Relative 13C enrichment under control or acidosis conditions
for glucose (B), CO2 (C), lactate (D), glutamate (E), ribonucleic acids (F), and fatty acids (G). Lactate (D) is presented as the total
13C labeled
lactate pool as well as 1 (C1) and 2 (C2) labeled carbon subpools. Glutamate (E) is presented as both the 2 (C2) and 4 (C4) labeled subpools.
Ribonucleic acids (F) are presented as the 13C positions 1 to 4 and 13C positions 3 to 5 subpools. Fatty acids (G) are presented as 2-carbon
13C-labeled palmitate and oleate. Error bars are mean ± SD, significant P values are indicated (*P ≤0.05, **P ≤0.01, ***P ≤0.001).
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tremely sensitive to acidosis. Our findings confirm several
previously reported metabolic adaptations to acidosis,
namely increased TCA cycle metabolism (increased
labeled glutamine) and decreased glycolysis (decreased
total labeled lactate production). More striking, however,
is the induction of the oxidative branch of the PPP,
coupled with a dramatic decrease in ribose labeling
from glucose. While the decrease in total ribonucleic
acid labeling may simply indicate decreased cellular
proliferation under acidosis, the induction of glucose to
the oxidative branch of the pentose phosphate pathway
(indicated by C1-labeled lactate (Figure 1D)) indicates
an increased need for reductive potential under acid-
osis. Glucose intermediates from the oxidative PPP rep-
resent the building blocks of ribose synthesis, so the
disconnect between increased oxidative PPP activity
(Figure 1D) and reduced ribose synthesis (Figure 1F)suggests that the metabolic intermediates of the non-
oxidative branch may be drawn away from ribose syn-
thesis towards glycolysis and the TCA cycle.
The influence of acidosis on palmitate and
glutamine metabolism
We compared the contribution of U13C glutamine to the
same group of metabolites Figure 2A under control or aci-
dosis (the relative changes are indicated in Figure 2, while
the complete data sets, presented as ONCOisobolome
matrix tables, are shown in Additional file 1: Tables S4
and S5). A similar media level of 13C5-labeled glutamate
indicated equal availability of extracellular glutamine
throughout the experiment (Figure 2B). Acidosis signifi-
cantly increased the levels of total labeled 13C-CO2 pro-
duced from glutamine (Figure 2C) and partially labeled
glutamate (Figure 2D), indicating increased utilization of
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Figure 2 The use of 13C glutamine isotope tracer to analyze glutamine metabolism under acidosis. (A) Schematic graph indicating
various measured metabolites (and corresponding panels) resulting from the uniformly 13C labeled glutamine tracer (green). The 13C labeled and
unlabeled carbons are indicated in red and black, respectively. (B-G) Relative 13C enrichment in the glutamate (B,D), CO2 (C), lactate (E),
ribonucleic acids (F) and fatty acids (G) under control or acidosis conditions. Glutamate (B,D) is presented as both the 2 (C2 (D)) and 4 (C2 (B))
labeled carbon subpools. Lactate (E) is presented as the uniformly labeled 13C3-labeled lactate. Ribonucleic acids (F) are presented as the 13C positions
1 to 4 and 13C positions 3 to 5 subpools. Fatty acids (G) are presented as 2-carbon 13C-labeled palmitate and oleate. Error bars are mean ± SD,
significant P values are indicated (*P ≤0.05, **P ≤0.01, ***P ≤0.001).
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consistent with both reduced lactate production and de-
creased malate shuttling, suggesting complete TCA me-
tabolism. Acidosis also increased the ribonucleic acid
labeling from glutamine, in particular 13C3-5 labeled ribose
(Figure 2F). Glutamine-derived intermediates can label ri-
bose via export from the mitochondria followed by entry
into the non-oxidative branch of the PPP, so increased la-
beling of ribose by glutamine suggests an induction of the
non-oxidative branch of the PPP. Finally, we observed no
change in the labeled fatty acids under acidosis with theU13C glutamine tracer, suggesting similar rates of fatty
acid synthesis (Figure 2G). This also indicates that there is
no significant reduction carboxylation of glutamate, under
acidosis alone, a notable difference from the cellular adap-
tations to hypoxia.
We then examined how acidosis affects palmitate meta-
bolism using (U)13C palmitate for similar group of metabo-
lites (Additional file 2: Figure S2A). The relative changes are
displayed in Additional file 2: Figure S1, while the complete
data sets are presented as ONCOisobolome matrix tables in
Additional file 1: Tables S6 and S7) and found that acidosis
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file 2: Figure S1B), increased total labeled 13C-CO2 be-
ing produced from palmitate (Additional file 2: Figure
S1C) and increased 13C2-labeled and 13C4-labeled glu-
tamate (Additional file 2: Figure S1D). Collectively,
these changes suggest that acidosis triggers an increase
in the β-oxidization of palmitate to acetyl-CoA and
subsequent feeding into the TCA cycle. Interestingly,
there was a dramatic decrease in total 13C-labeled lac-
tate levels (Additional file 2: Figure S1E), suggesting de-
creased malate shuttling. Ribose labeling from palmitate
was also increased, in particular 13C3-5 labeled ribose
(Additional file 2: Figure S1F). Finally, acidosis did not
cause significant changes in labeled oleate from palmitate
(Additional file 2: Figure S1G). The observed increase in
β-oxidation would lead to both increased TCA cycle turn-
over and increased cellular NADPH generation, while the
increase labeling of both ribose and 4-carbon-labeled
glutamate suggested increased shuttling of TCA cycle
intermediates to the cytosol, for use in either the non-
oxidative PPP or recycling through glycolysis. Overall,
our findings from the palmitate tracer indicate a pattern
of metabolic reprogramming that is consistent with that
seen for the glucose and glutamine tracers.
The importance of glutaminolysis for metabolic
adaptations under acidosis
Previous studies have indicated an increased reliance
upon mitochondrial metabolism under acidosis [5,36],
and the glutamine tracer experiments further support a
major role for increased glutaminolysis in the increase in
TCA cycle. To further examine how acidosis affects glu-
tamine and other amino acids, we measured the intracel-
lular levels of 15 amino acids in MCF-7 cells when
exposed to 10 mM and 25 mM LA (pH 6.7) to represent
the medium and upper range of tumor lactate [37] and
acidity [13,34]. While both acidosis and lactic acidosis
increased the levels of most amino acids (such as valine
and leucine/isoleucine; Additional file 3: Figure S2A),
they significantly reduced Glx (glutamine plus gluta-
mate) (Figure 3A). When independent methods were
used to resolve glutamine vs. glutamate in the Glx ana-
lysis, we found that acidosis reduced the intracellular
levels of both glutamine and glutamate (Figure 3B). This
depletion of glutamine and glutamate, in light of a general
increase in most other amino acids, further support in-
creased glutaminolysis under acidosis (Figure 2D).
However, given that acidosis has been shown to inhibit
uptake of glucose [5], we wished to test how acidosis af-
fects glutamine uptake by either consumption of gluta-
mine in media (Additional file 3: Figure S2B) or cellular
uptake of 14C-labeled glutamine (Additional file 3: Figure
S2C). In both cases, we observed that acidosis increased
both glutamine consumption and uptake. Therefore, thereduced glutamine/glutamate levels under acidosis are
likely due to an increase in consumption (glutaminoly-
sis) instead of reduced uptake. This represents an addi-
tional line of evidence that cells exposed to acidosis are
increasingly reliant upon glutamine.
Next, we examined cellular phenotypes when cells
were deprived of glutamine under acidosis. While MCF-
7 and ZR75-1 cells were mostly glutamine-independent
under neutral pH, glutamine deprivation under acidosis
significantly decreased both cell numbers and ATP levels
at either 4 or 24 h (Figure 3C,D, and Additional file 3:
Figure S2B). The decrease in cell numbers associated
with the combination of both acidosis and glutamine
deprivation was comparable to the decrease under glucose
deprivation, yet was largely absent when only acidosis
or glutamine deprivation was present (Figure 4C).
Figures 3C,D together suggest that at least one important
role glutamine has under acidosis is ATP generation
(bioenergetics). Glutamine can be used to generate ATP via
anapleurosis, in which glutamine is sequentially converted to
glutamate and then to α-KG to enter the TCA cycle.
Therefore, we next investigated how acidosis affected
various enzymes involved in glutamine anapleurosis. Glu-
tamine and glutamate are able to reciprocally interconvert
via the activity of two enzymes: glutamine synthetase (GS,
encoded by GLUL) and glutaminase (encoded by GLS and
GLS2). We previously demonstrated that MCF-7 and
other luminal breast cancer cells only expressed GLS2
[38]. Both acidosis and lactic acidosis induced GLS2
mRNA and protein (Figure 3E,F) levels while repressing
the level of GS protein (Figure 3F). TXNIP, a gene previ-
ously shown to be induced under acidosis [36], served as a
positive control. Such changes may explain the increased
glutaminolysis and reduction in the intracellular gluta-
mine under acidosis. The silencing of GLS2 (Additional
file 3: Figure S2D) considerably reduced cell numbers
under acidosis (Figure 3G, Additional file 3: Figure S2E, F)
in both MCF-7 and ZR-75-1 cells. Therefore, GLS2 induc-
tion and increased glutaminolysis were important for cell
survival under acidosis.
A major role of glutamine and glutamate in cellular
metabolism is, in combination with cysteine and glycine,
the generation of glutathione for neutralizing reactive
oxygen species. We therefore examined the glutathione
status under acidosis and found that acidosis drama-
tically increased the GSSG (oxidized glutathione)/GSH
(reduced glutathione) ratio and lowered the anti-stress
capacity of cells after 24 h (Figure 3H). This increase in
GSSG/GSH ratio was due to a simultaneous increase in
GSSG levels coupled with a decrease in total glutathione
levels (Figure 3I, Additional file 4: Figure S3A).
Both lactic acidosis and acidosis had a similar (ap-
proximately 40%) reduction in GSH levels (Figure 3I,
Additional file 4: Figure S3A), suggesting that the effect
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Figure 3 (See legend on next page.)
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Figure 3 Acidosis increases glutaminolysis and renders glutaminolysis essential. (A) Heatmap shows the changes in the intracellular amino
acids under acidosis (HCl), lactosis (10 and 25 mM Lac), or lactic acidosis (10 and 25 mM LA) (n = 3) conditions. (B) Normalized levels of
intracellular glutamine (Gln) and glutamate (Glu) in MCF-7 cells under control or lactic acidosis conditions (n = 4). (C) Relative cell numbers as
determined by trypan blue exclusion, of MCF-7 and ZR-75-1 cells after 72 h under the indicated media conditions. (n = 4) (D) Relative ATP levels
under acidosis (Acid) with (+) or without (-) of glutamine (Gln) in media. (E,F) Relative changes of indicated mRNAs (E) and proteins (F) under
indicated conditions. (G) Relative cell numbers of MCF-7 cells when transfected with control or two GLS2 small interfering (si)RNAs under control
and acidosis conditions. (H) Total glutathione (GSH) level of MCF-7 cells exposed to acidosis or lactic acidosis (n = 3). (I) Normalized glutathione
disulfide (GSSG)/GSH ratios for MCF-7 and ZR-75-1 cells under control, acidosis or lactic acidosis conditions (n = 6). (J) Normalized cell numbers of
MCF-7 cells under control, acidosis and lactic acidosis conditions when exposed to indicated level (uM) of H2O2 (n = 3). (K,L) Relative cell numbers
(via trypan blue exclusion) (K) and cellular ATP level for MCF-7 (L) treated with vector or 0.2 mM amino-oxyacetate (AOA) for 72 h. The
indicated samples were supplemented with 700 μm α-ketoglutarate (α-KG). Error bars are mean ± SEM, P values as indicated (*P ≤0.05,
**P ≤0.001, ***P ≤0.0001).
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lar NADP+/NADPH and GSSG/GSH ratios, as well as
total GSH (Additional file 4: Figure S3B-D) were also re-
duced, though not to the same degree, after 5 h of ex-
posure to acidosis, similar to what was seen for cellular
ATP levels (Additional file 3: Figure S2B).
These data suggest that these cellular adaptations to
acidosis are progressive in nature and increase over the
course of exposure to acidosis.
Consistent with compromised anti-stress capacity re-
flected in a higher GSSG/GSH ratio, both acidosis and
lactic acidosis reduced the survival of MCF-7 cells under
different levels of H2O2 (Figure 3J). To determine why
total glutathione levels were decreased under acidosis,
we examined the RNA levels of genes involved in the
GSH synthesis [7]. We found that both subunits (GCLC
and GCLM) of the enzyme glutamate-cysteine ligase,
which catalyzes the first and rate-limiting step of GSH
synthesis, were significantly downregulated under lactic
acidosis (Additional file 5: Figure S4A). This decrease in
GCLC and GCLM RNA levels was coupled with a de-
crease in NRF2 activity (Additional file 5: Figure S4B)
under lactic acidosis, suggesting that acidosis (and/or
lactic acidosis) decouples the reduced glutathione syn-
thesis from glutaminolysis via inhibition of NRF2-
regulated transcriptional activity. Since acidosis increases
ROS levels within the cells, we wondered whether over-
expression of NRF2 would reduce cellular ROS and miti-
gate the reduced viability under acidosis. Surprisingly,
while NRF2 did lead to increased mRNA levels of GCLC
and GCLM (Additional file 5: Figure S4C), it also caused
a far greater decrease in cellular proliferation under
acidosis (Additional file 5: Figure S4D). This decrease in
cell numbers when NRF2 is overexpressed under acid-
osis was correlated with a decrease in intracellular glu-
tamine and glutamate (Additional file 5: Figure S4E),
suggesting that redirection of glutamine and glutamate
under acidosis is necessary for cell growth.
The redirection of glutamate away from GSH synthesis
was quite striking, so we further examined the cellular
requirement for glutamate under acidosis. Our stableisotope tracer data suggested that glutamine was in-
creasingly redirected towards mitochondrial metabolism
under acidosis (Figure 2D). The entry of glutamate into
the TCA cycle requires the conversion of glutamate to
α-KG, which occurs via either deamination or trans-
amination. Glutamate deamination in non-neuronal cells
is catalyzed by glutamate dehydrogenase 1 (GDH), en-
coded by GLUD1. Transamination, by contrast, is medi-
ated by several classes of transaminases. Extracellular
acidosis led to the specific downregulation of GLUD1,
suggesting that glutamate deamination may not play a
critical role in the cellular acidosis response (Additional
file 5: Figure S4F) with TXNIP induction as positive
control acidosis. Therefore, we tested the importance of
glutamate transamination by determining how amino-
oxyacetate (AOA), a chemical inhibitor of transamination,
impacts cellular survival under acidosis. Cells treated with
0.2 mM AOA showed dramatically decreased cell num-
bers only under acidosis (Figure 3K), suggesting an im-
portant role for transamination under acidosis. We also
found that membrane-permeable dimethyl α-KG signifi-
cantly restored cell numbers (Figure 4K) and ATP levels
(Figure 3L) of MCF-7 cells exposed to AOA under lactic
acidosis. Similar synthetic lethality of AOA under acidosis
and rescue by dimethyl α-KG was also observed for ZR-
75-1 cells (Additional file 5: Figure S4G). Together, these
results indicate that both acidosis redirects cellular glu-
tamine to the TCA cycle for cellular bioenergetics (ATP
generation), which leads to depletion of other glutamine-
dependent metabolites, such as GSH.
Redirection of glucose and the importance of NADPH to
the cellular acidosis response
Collectively, the stable-isotope tracing experiments indi-
cated that acidosis redirected glucose away from glycoly-
sis and lactate production towards both the TCA cycle
and the PPP. We therefore examined why cells would
redirect glucose in this fashion, especially in light of the
increased glutaminolysis and reduced GSH production.
When the pentose-cycle flux was calculated based upon
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LaMonte et al. Cancer & Metabolism 2013, 1:23 Page 11 of 19
http://www.cancerandmetabolism.com/content/1/1/23
(See figure on previous page.)
Figure 4 Acidosis enhanced oxidative branch of pentose phosphate pathways (PPPs). (A) Percentage of glucose that enters the PPP under
control or acidosis conditions. (B) NADP+/nicotinamide adenine dinucleotide phosphate (NADPH) ratio for MCF-7 and ZR-75-1 cells under control or
acidosis conditions (n = 6). (C) Heatmap indicates the transcriptional changes of genes listed by the Kyoto Encyclopedia of Genes and Genomes (KEGG)
in the PPPs under hypoxia, lactic acidosis or glucose deprivation conditions. (D) Genes in PPP were induced (red) or repressed (green) by at least
1.7-fold under lactic acidosis. (E) The mRNA expression of glucosephosphate isomerase (GPI), glucose-6-phosphate dehydrogenase (G6PD), transketolase
(TKT), and triose phosphate isomerase (TPI) under control or acidosis conditions with 0, 4, 10 and 25 mM lactate. (F) The protein levels of G6PD, TKT
and β-tubulin in MCF-7 cells under acidosis, lactosis (25 mM), or lactic acidosis (10 mM and 25 mM pH 6.7) conditions with the relative changes (by
densitometry) shown. (G) Relative cell numbers of MCF-7 cells that have been transfected with control or two small interfering (si)RNAs targeting G6PD
under control or acidosis conditions. (H) Relative NADP+/NADPH ratios in MCF-7 cells, transfected with control or two G6PD-targeting siRNAs, under
control or acidosis conditions (n = 4). (I) Relative ROS in MCF-7 cells transfected with control or two G6PD-targeting siRNAs, under control or acidosis
conditions. (J) Relative cell numbers of MCF-7 cells transfected with control or TKT-targeting siRNA under control or acidosis conditions (A). Error bars
are mean ± SEM, P values as indicated (*P ≤0.05, **P ≤0.001, ***P ≤0.0001).
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from 4% to 5% under acidosis (Figure 4A). Since the extra-
cellular glucose pool was 50% labeled, this change would
correspond to an increase from 8% to 10% of total glucose
entering the PPP. Since two NADPH are generated per
single redirected glucose molecule, this 25% increase in
PPP should generate considerably more NADPH. Indeed,
we found that acidosis significantly increased the re-
ductive capacity of cells, as indicated by a reduced
NADP+/NADPH ratio, by 28% in MCF-7 cells and 39%
in ZR-75-1 cells (Figure 4B). This decrease in the
NADP+/NADPH ratio was generated by both a de-
crease in NADP + levels and an increase in NADPH
levels (Additional file 6: Figure S5A).
To investigate the causes for increased PPP under acid-
osis, we examined the transcriptional response of PPP
genes listed in the Kyoto Encyclopedia of Genes and Ge-
nomes (KEGG) in a previously reported microarray data
[6] (Figure 4C,D). While the published data focused on lac-
tic acidosis, the strong concordance reported between the
acidosis and lactic acidosis responses [5] provides the ra-
tionale to use this data to investigate the acidosis response
of MCF-7 cells. Analysis of the microarray data for all the
KEGG-listed PPP genes indicated that lactic acidosis in-
duced the expression of G6PD, TKT and triose phosphate
isomerase (TPI) (Figure 4C,D). The induction of these
genes under acidosis was further verified using real-time
PCR in MCF-7 (Figure 4E) and ZR-75-1 cells (Additional
file 6: Figure S5B). In addition to increased mRNA expres-
sion, we observed G6PD induction at the protein level
under both acidosis and lactic acidosis (Figure 4F) and
both MCF-7 and ZR-75-1 cells had increased intracellular
G6PD activity under acidosis (Additional file 6: Figure
S5C). Since G6PD encodes the first and rate-limiting step
of the oxidative branch of the PPP the increased G6PD
RNA, protein and activity levels may explain the increase
in the oxidative PPP activity under acidosis.
To test this possibility, we determined the impact of
silencing of G6PD on cell numbers under control or
acidosis conditions. While acidosis alone reduced cell num-
bers by approximately 20%, the silencing of G6PD by twoseparate siRNAs (Additional file 6: Figure S5D) further
reduced cell numbers by approximately 60%, as assayed
after 96 h, by either trypan blue exclusion or PI incor-
poration, for both MCF-7 and ZR-75-1 cells (Figure 4G,
Additional file 6: Figure S5E-G). Similarly, a PPP inhibitor,
6-aminonicotinamide (6-AM), also exhibited similar
acidosis-specific reduced survival (Additional file 6: Figure
S5H). In contrast, 2-deoxyglucose (2-DG), an inhibitor of
glycolysis, improved survival under acidosis (Additional
file 6: Figure S5H). Collectively, these data suggest that
G6PD and the PPP are critical for cellular survival under
acidosis.
We then investigated why G6PD is critical for cellular
survival under acidosis. The oxidative branch of the PPP
is important for generating NADPH, an important re-
ducing equivalent for lipogenesis and neutralizing
ROS. Since there is no increase in fatty acid synthesis
(Figure 1G), NADPH generated by G6PD may be required
for ROS neutralization. Silencing G6PD further mitigated
the decrease in NADP+/NADPH (Figure 5H) and in-
creased the levels of ROS under acidosis (Figure 4I).
These data suggest that G6PD is essential for the gener-
ation of NADPH to neutralize the increased ROS under
acidosis.
Finally, our stable isotope tracer data for both gluta-
mine and palmitate (Figure 2F, and Additional file 2:
Figure S1F) also indicated that acidosis induced the
non-oxidative branch of the PPP. The non-oxidative
branch of the PPP, which reversibly returns PPP inter-
mediates back to glycolysis, is primarily mediated by
two enzymes, TKT1 and transaldolase. To test whether
induction of the non-oxidative branch of the PPP was
critical to the cellular response to acidosis, we assessed
cell proliferation under acidosis after siRNA silencing of
TKT1. While not as severe an effect as observed for G6PD,
the combined silencing of TKT and exposure to acidosis re-
duced cell proliferation by approximately 50% after 72 h
(Figure 4J). This suggests that while glucose is redirected to
the PPP, cells also require glucose-based PPP intermediates
to be redirected back to glycolysis, which may explain the
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Figure 5 Regulation of the metabolic response to acidosis by p53. (A) Protein levels of p53 under control, lactosis, acidosis (HCl) and lactic
acidosis (LA). (B-D) Relative mRNA expression of p21, p53 and MDM2 genes in the shControl or shP53 MCF-7 cells under control or acidosis
conditions. (C) Relative mRNA expression and protein levels of GLS2 in shControl or shP53 MCF-7 cells under control or acidosis conditions. (D)
Relative ATP levels in shControl or shp53 cells under lactic acidosis (LA) with (+) or without (-) glutamine. (E) Relative mRNA expression and
protein levels of glucose-6-phosphate dehydrogenase (G6PD) in shControl or shP53 MCF-7 cells under control or acidosis conditions. (F-H) Relative
NADP+/nicotinamide adenine dinucleotide phosphate (NADPH) ratio (F), normalized ROS levels (G), and normalized cell numbers (H) in shControl or
shP53 MCF-7 cells under control or acidosis conditions. Error bars are mean ± SEM, P values as indicated (*P ≤0.05, **P ≤0.001, ***P ≤0.0001).
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response to acidosis
Next, we wanted to identify potential regulators of the ob-
served metabolic reprogramming under acidosis. Many
studies have indicated that both enhanced PPP and in-
creased mitochondrial metabolism can be triggered by the
activation of the tumor suppressor p53 [39]. Furthermore,
there is a highly positive correlation between the lacticacidosis response elicited in MCF-7 cells and the p53
pathways in the breast tumor datasets [8]. Acidosis also
decreased malate flux from the TCA cycle (Figure 1E,
Additional file 2: Figure S1E), a process that was recently
shown to be inhibited by p53 [40]. Based upon these pre-
vious findings, we hypothesized that p53 may play a role
in the metabolic response to acidosis. Consistent with that
hypothesis, we found that acidosis increased p53 protein
LaMonte et al. Cancer & Metabolism 2013, 1:23 Page 14 of 19
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andMDM2, two well-known p53 target genes (Figure 5B).
Therefore, we tested whether p53 may play a role in the
metabolic response of acidosis by comparing isogenic
groups of MCF-7 cells with or without p53 by stably
expressed small hairpin (sh)RNAs (Additional file 7:
Figure S6A) [22]. First, we noted that the induction of
GLS2 mRNA and protein under acidosis was abolished in
the p53-deficient cells (Figure 5C). The reduced ATP during
glutamine deprivation and lactic acidosis was also largely
abolished when p53 was inhibited (Figure 5D). These re-
sults indicate the GLS2 induction and altered glutamine
metabolism under acidosis is a p53-dependent process.
Similarly, we found that either the genetic or chemical
silencing of p53 abolished the induction of G6PD mRNA
and protein under acidosis (Figure 5E, Additional file 7:
Figure S6B,C). Consistent with the role of p53 in the en-
hancement of the PPP, the silencing of p53 also signifi-
cantly increased both NADP+/NADPH ratio (Figure 5F)
and ROS (Figure 2G), similar to the silencing of G6PD
(Figure 4I,J). p53 mediation of these metabolic adaptations
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Figure 6 Glucose-6-phosphate dehydrogenase (G6PD) and p53 status
indicated cell lines under control or acidosis conditions. (B) Relative mRNA
acidosis conditions. (C,D) Relative NADP+/nicotinamide adenine dinucleoti
indicated cell lines under control or acidosis conditions. (E) Relative expres
wild-type or mutant p53.proliferation, as p53-deficient cells also have dramatically
reduced cellular proliferation under acidosis (Figure 5H).
Furthermore, acidosis failed to induce GLS2 and G6PD
in several breast cancer cell lines with mutated p53
(T47D and MDA-MD-231) (Figure 6A,B, Additional file 7:
Figure S6D). Finally, two cell lines with mutated p53 also
showed decreases in the reductive capacity (increased
NADP+/NADPH ratio) (Figure 6C) and higher levels of
ROS (Figure 6D) under acidosis. Therefore, p53 activation
under acidosis is responsible for the induction of both glu-
taminolysis and the oxidative branch of the PPP to miti-
gate the oxidative stress under acidosis.
p53 is known to transcriptionally regulate a number of
genes involved in cellular metabolism. However, given
the lack of induction of GLS2 under acidosis when p53
was genetically inhibited, we wanted to examine loss of
GLS2 induction could account for the lack of adaptive
response in the cells without p53. To test this possibility,
we forced the expression of GLS2 by transfecting GLS2
and empty vectors in the control and p53-knockdown
MCF-7 cell lines. When these cells were placed under
































are correlated in vivo. (A) Relative mRNA expression of GLS2 in the
expression of G6PD in the indicated cell lines under control or
de phosphate (NADPH) ratio (C) and normalized ROS levels (D) in the
sion level of G6PD mRNA in among groups of breast tumors with
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the increased ROS, increased NADP+/NADPH ratio
and mitigates the decrease in cell numbers seen when
p53 is genetically inhibited under acidosis (Additional
file 7: Figure S6E-G). These data strongly suggest that
the p53-dependent GLS2 induction play an important role
in the anti-stress capacity under acidosis. However, other
p53 targets may also play a role in the adaptive cellular re-
sponse to extracellular acidosis.
To extend the relationship between p53 and G6PD, we
examined their relationship in vivo using a breast cancer
dataset with known p53 status [41]. Tumors with wild-type
p53 (n = 72) had significantly higher G6PD expression than
p53 mutant tumors (n = 179) (Figure 6E), indicating that
the connection between p53 activity and G6PD expression
extends beyond cell lines to human tumors as well.
Discussion
Relatively little is known about the cellular metabolic re-
sponse to acidosis found in most solid tumors. Here, we
employ isotope tracer experiments to make several im-
portant observations on how acidosis affects glucose,
glutamine and palmitate metabolism. Besides confirming
previous observations of reduced glycolysis and lactate
production [6,7], these experiments revealed that extra-
cellular acidosis increased oxidative PPP (Figures 1 and 4),
glutaminolysis (Figure 2) and β-oxidation of fatty acids
(Additional file 2: Figure S1). Interestingly, acidosis also
abolished most of the conversion of glucose to ribose for
ribonucleotide synthesis via the PPP. Since the decrease in
ribose conversion (approximately 90%) far exceeds the re-
duction in proliferation (approximately 30% in 3 days),
there is possibly enzymatic inhibition or reversed meta-
bolic flow in the non-oxidative PPP under acidosis. Such
increased oxidative PPP and reduced ribose production
under acidosis is reminiscent of the metabolic patterns of
the quiescent fibroblasts [42]. These metabolic adaptions
allow cells to cope with the demand for bioenergetic needs
(ATP) and reducing equivalents (NADPH) necessary for
survival, while reducing the biosynthetic requirements
(that is, ribonucleotides) of cellular proliferation. These
changes are also consistent with the starvation response
[6] and increased autophagy [16,43] under acidosis. The
diversion of glucose to the PPP may further increase the
need for TCA metabolites, which can be supplied from
the increased glutaminolysis and fatty acid β-oxidation. A
similar increased need for NADPH and glutaminolysis has
been observed for other metabolic stresses, such as hy-
poxia [44], glucose deprivation [45] and matrix detachment
[46]. Therefore, these shared metabolic adaptations may
underlie common mechanisms of cellular responses to
various tumor environmental stresses within solid tumors.
We also identified a critical role for p53 in coordinating
various metabolic responses to acidosis. The increase inmitochondria function (for ATP generation) and the oxi-
dative branch of the PPP (for NADPH to neutralize ROS)
are both known functions of p53 in (1) promoting cata-
bolic pathways to maintain energy production during nu-
trient starvation; (2) ameliorating oxidative stress; and (3)
inhibiting cell growth and cell cycle progression. Acidosis
also reduces glycolysis [5,6], which is another prominent
metabolic feature downstream of p53 through the induc-
tion of TP53-inducible glycolysis and apoptosis regulator
(TIGAR) [47] and downregulation of glucose transporters
[48] and phosphoglycerate mutase [49]. The induction of
GLS2 and increased glutaminolysis under acidosis, while
novel, is also consistent with the function of p53 to
promote ATP production and antioxidant function [24,50].
p53 has also been shown to downregulate NRF-2-mediated
transcription [51], suggesting that the decrease in GSH
synthesis under acidosis, due to downregulation of GCLC
and GCLM, is also consistent with increased p53 activity
under lactic acidosis. Therefore, the response to extracellu-
lar acidosis may represent a novel tumor suppressor func-
tion of p53. Furthermore, the dependence of the acidosis
response on p53 may explain the higher degree of lactic
acidosis transcriptional responses in breast tumors with
wild-type p53 [5,8] even though these tumors, when com-
pared tumors with mutant p53, have lower levels of lactic
acidosis, glycolysis and hypoxia [8].
G6PD encodes the first and rate-limiting enzyme of
the oxidative PPP. Therefore, the increase in both G6PD
expression and activity under acidosis (Figure 5) is im-
portant for the enhanced oxidative PPP activities. Several
mechanisms are likely to account for the increase in
G6PD activity under acidosis by p53. We noted a p53-
dependent transcriptional induction of G6PD, consistent
with a previous report of G6PD as transcriptional target
of p53 [52]. The increased NADP+/NADPH under acid-
osis may also activate G6PD allosterically [45]. Cytoplas-
mic p53 has been reported to inhibit G6PD protein
directly through protein-protein interaction [40], so it is
possible that acidosis may reduce the interaction by
lowering cytoplasmic pools of p53 or pH-dependent
conformational changes. While the contribution of indi-
vidual factors remains to be determined, the induction
of G6PD is likely an important adaptation under acidosis
when cells become susceptible to genetic and chemical
inhibition of G6PD.
While this study provides many new insights of cellular
metabolism under acidosis, many aspects of the metabolic
adaptations of cells to acidosis still remain unknown. For
example, we still do not understand how acidosis en-
hances the oxidative PPP while abolishing ribonucleotide
production via the non-oxidative PPP. Such disso-
ciation between these two branches of the PPP has
been previously described for Ras-driven pancreatic
cancers [53] and may save the cells from wasting
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http://www.cancerandmetabolism.com/content/1/1/23glucose metabolites in nucleotide biosynthesis given
the lack of proliferation under acidosis. However, we also
observe an increase in the flow of TCA cycle metabolites,
via the non-oxidative branch of the TCA cycle, into ribose
labeling. Thus, it is clear that some of the TCA cycle com-
ponents are being used for non-bioenergetic purposes
under acidosis, though the mechanism by which TCA me-
tabolites, potentially including increased export of citrate
and malate, enter the cytosol remains unclear. However,
glutamine and palmitate contribute only a low level of ri-
bose synthesis, which would appear to be insufficient to
compensate for the loss of glucose labeling of ribose. This
leads us to conclude that a combination of metabolites,
potentially including glycerol from the fetal bovine serum
and potentially circulating triglycerides in humans, not
just glutamine or palmitate, contribute to the labeling of
ribose under extracellular acidosis.
Furthermore, while we investigated the transcrip-
tional response of G6PD and GLS2, there are likely to
be additional regulators of the acidosis response, at either
the transcriptional, translational or post-translational level.
For example, p53-responsive TIGAR may also play a role
in the shunting of glucose to PPP for NADPH [39] under
acidosis. The roles of additional regulators and meta-
bolic flow will be studied in detail in the future to gain a
more complete understanding of the metabolic response
to acidosis.
The in vivo relevance of many of our observations on















Figure 7 Overview of the metabolic reprogramming mediated by p53
(G6PD) is induced under acidosis by p53, which increases nicotinamide ade
to help cells tolerate the increased ROS stresses and reduced novel GSH sy
the novel RNA ribose synthesis via the PPP. Furthermore, the activation of
GLS2, leading to increased glutamate generation, which is then converted to
Enzymes are underlined and in bold.independently confirmed in other systems and disease set-
tings. For example, metabolic acidosis is noted to increase
glutaminolysis in intact nephron and rodent models, pos-
sibly mediated by increased glutaminase (GLS) mRNA sta-
bility [54]. Previous studies have noted the regulation of
liver-type glutaminase (GLS2), glutamine metabolism and
antioxidative capacity by p53 in breast cancers [24,50].
The strong positive correlation of G6PD expression, the
acidosis transcriptional response and p53 status further
support the role of p53 in inducing G6PD and other cellu-
lar acidosis responses (Figure 7). It is also worth noting
that the G6PD locus is locally amplified in breast and
other tumors in Tumorscape [55]. Such hardwired DNA
amplification may confer a robust PPP and a selective
advantage within the tumor microenvironmental stresses.
Tumor acidosis is often associated with metastasis and
resistance to cancer therapeutics in patients [6,7]. Inter-
estingly, the two major changes we observed here in
cancer cells under acidosis, elevated levels of G6PD and
increased PPP, both of which show the importance of
the regeneration of reducing equivalents to cancer pro-
liferation, are also both also associated with brain metas-
tasis [56,57] and drug resistance [58,59]. Additionally,
extracellular acidosis forces breast cancer cells to engage
in a series of dysregulated metabolic adaptations in order
to adapt to the changing extracellular environment. Since
increased oxidative stress, as occurs in response to
acidosis, is associated with metastasis and drug resistance,







under acidosis conditions. Glucose-6-phosphate dehydrogenase
nine dinucleotide phosphate (NADPH) from the oxidative PPP appears
nthesis under acidosis conditions. Acidosis also dramatically reduces
p53 under acidosis contributes to increased glutaminolysis by inducing
α-ketoglutarate (α-KG) and enters the tricarboxylic acid cycle (TCA cycle).
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metabolic changes under acidosis could also reflect a
novel tumor suppressive role for p53; while p53 pro-
motes TCA cycle metabolism, it also induces the PPP to
mitigate the increased ROS and DNA instability from
TCA metabolism, which ultimately impedes tumor pro-
gression. Together, the data presented here provide sev-
eral novel insights into both the short-term metabolic
adaptations of cancer cells under acidosis, as well as the
long-term potential impact of acidosis to exert selective
pressures upon the somatic mutations within human
tumors.
Conclusions
Taken together, our metabolomic analysis of the acid-
osis responses indicates a significant reprogramming of
cellular metabolism toward the oxidative PPP and glu-
taminolysis through the induction of G6PD and GLS2,
respectively (Figure 7). The increase in the NADPH
from the oxidative PPP appears to be required to help
cells to better tolerate the increased ROS stress and re-
duced novel GSH synthesis under acidosis. Further-
more, p53 plays an important role in coordinating the
metabolic response to acidosis by inducing G6PD (redirec-
tion to the PPP) and GLS2 (increased glutaminolysis).
Such metabolic adaptations under acidosis may render
cancer cells susceptible to inhibition of glutamate meta-
bolism and/or NADPH generation.
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indicating the measured metabolites (and corresponding panels)
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or acidosis conditions. The relevant substrate tracer is indicated in green, 13C
labeled carbons are indicated in red (normal carbon atoms are black). (B-G).
Relative 13C enrichment in the palmitate (B), CO2 (C), glutamate (D), lactate
(E), ribonucleic acids (F) and oleate (G) under control or acidosis conditions.
Glutamate (D) is presented as both the 2 (C2 (E)) and 4 (C4 (B)) labeled
carbon subpools. Lactate (E) is presented as the total 13C-labeled lactate
pool. Ribonucleic acids (F) are presented as the 13C positions 1 to 4 subpool.
Fatty acids (B,G) are presented as 2-carbon 13C-labeled palmitate (B) and
oleate (G). Error bars are mean ± SD, significant P values are indicated
(*P ≤0.05, **P ≤0.01, ***P ≤0.001).
Additional file 3: Figure S2. Essential role of glutaminolysis under
acidosis. (A) The intracellular levels of Val and Leu/Ile under indicatedconditions of acidosis or lactic acidosis conditions (n = 3). (B) Normalized
cellular ATP levels in MCF-7 cells under control or acidosis conditions
after 4 h. (C) Measurements of glutamine in cell culture media at 5 and
24 h after exposure to acidosis. (D) 14C-glutamine levels in cell pellets
under control or acidosis conditions in MCF-7 cells at 1 h and 12 h. (E)
Levels of the indicated proteins in the glutamine/glutamate metabolism
pathways after the gene silencing by respective small interfering (si)RNAs.
(F,G) Relative cell numbers (as a ratio of acidosis/control) of MCF-7 (F)
and ZR-75-1 (G), determined by propidium iodide staining, when the
indicated genes were silenced under normal or acidosis conditions
(n = 3). Error bars are mean ± SD, significant P values are indicated
(*P ≤0.05, **P ≤0.01, ***P ≤0.001).
Additional file 4: Figure S3. Effects of acidosis on glutathione (GSH)/
glutathione disulfide (GSSG) and NADP+/nicotinamide adenine
dinucleotide phosphate (NADPH) after 5 h of exposure (A) Normalized
total GSH and GSSG levels for MCF-7 and ZR-75-1 cells under control or
acidosis conditions (pH 6.7). (B-D) NADP/NADPH ratio, GSSG/GSH ratio,
normalized total GSH levels of MCF-7 cells after 5 h of either control or
acidosis conditions. Error bars are mean ± SD, significant P values are
indicated (*P ≤0.05, **P ≤0.01, ***P ≤0.001).
Additional file 5: Figure S4. Acidosis reduced nuclear factor erythroid
2-related factor 2 (NRF2) activities and increased levels of ROS. (A)
Relative mRNA abundance, determined by microarray and quantitative
real-time PCR (qPCR), for the indicated genes under control or lactic
acidosis conditions. (B) Relative NRF2 activity, as determined by luciferase
reporter, for MCF-7 cells exposed to control or lactic acidosis conditions.
(C) Relative mRNA levels of the indicated genes, after green fluorescent
protein (GFP) or NRF2 overexpression, as determined by qPCR. (D)
Relative cell numbers 48 h after the expression of GFP or NRF2 in MCF-7
cells under control or acidosis conditions. (E) Intracellular normalized levels
of glutamine and glutamate in MCF-7 cells that have been transfected with
GFP or NRF2 expression constructs. (F) Relative transcript abundance,
determined by microarray and qPCR, for the indicated genes under control,
acidosis (qPCR only) or lactic acidosis conditions. (G) Relative cell numbers
for ZR-75-1 cells treated with 0.2 mM amino-oxyacetate (AOA) or under
control or acidosis conditions. Indicated cells are also supplemented with
700 uM dimethyl α-ketoglutarate (α-KG) (n = 4). Error bars are mean ± SD,
significant P values are indicated (*P ≤0.05, **P ≤0.01, ***P ≤0.001).
Additional file 6: Figure S5. The effects of acidosis on the expression
of genes that encode proteins in the pentose phosphate pathways
(PPPs). (A) Normalized NADP + and nicotinamide adenine dinucleotide
phosphate (NADPH) levels in MCF-7 and ZR-75-1 cells under control and
acidosis conditions. (B) The acidosis-induced change of mRNA expression
for the indicated genes in MCF-7 and ZR-75-1 cells. (C) Relative glucose-6-
phosphate dehydrogenase (G6PD) activity in MCF-7 and ZR-75-1 cells under
control or acidosis conditions. (D) Protein levels of G6PD and transketolase
1 (TKT1) in MCF-7 cells transfected by control (siControl), two small
interfering (si)RNAs targeting G6PD (siG6PD), or siRNA targeting TKT1
(siTKT1). (E) Relative cell numbers of ZR-75-1 cells transfected with control
or siRNA targeting G6PD under control or acidosis conditions. (F,G) The
change in cell numbers of MCF-7 (F) and ZR-75-1 (G) cells, under acidosis,
treated with the indicated siRNAs determined by propidium iodide staining.
(H) Relative cell numbers of MCF-7 cells that have been treated with
dimethylsulfoxide (DMSO), 2-deoxyglucose (2-DG) or 6-aminonicotinamide
(6-AM) under control or acidosis conditions (n = 4). Error bars are mean ± SD,
significant P values are indicated (*P ≤0.05, **P ≤0.01, ***P ≤0.001).
Additional file 7: Figure S6. The role of p53 in the acidosis response.
(A) Protein levels of p53 in MCF-7 cells expressing shp53 or shControl.
(B) Glucose-6-phosphate dehydrogenase (G6PD) activity in MCF-7 cells
expressing shCon or shP53 exposed to either control or acidosis conditions.
(C) G6PD activity in the indicated cell lines exposed to either control or
acidosis conditions. (D) mRNA expression of the indicated genes exposed
to either control or pifithrin-α under normal or acidosis conditions. (E-G)
normalized ROS levels (E), NADP+/nicotinamide adenine dinucleotide
phosphate (NADPH) ratio (F) and normalized cell numbers (G) in the
shControl or shP53 MCF-7 cells when they were transfected with
either GLS2 or empty expression vector, under control or acidosis conditions.
Error bars are mean ± SEM, P values as indicated (*P ≤0.05, **P ≤0.001,
***P ≤0.0001).
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